Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Franklin Resources Inc.

Franklin Resources Inc. increased its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 6.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,773 shares of the company’s stock after purchasing an additional 1,720 shares during the period. Franklin Resources Inc. owned approximately 0.05% of Harmony Biosciences worth $1,191,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of HRMY. nVerses Capital LLC purchased a new stake in shares of Harmony Biosciences during the 2nd quarter worth about $36,000. CWM LLC boosted its stake in shares of Harmony Biosciences by 111.7% in the third quarter. CWM LLC now owns 1,469 shares of the company’s stock worth $59,000 after acquiring an additional 775 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Harmony Biosciences during the 3rd quarter worth $74,000. Quarry LP acquired a new position in Harmony Biosciences during the second quarter worth about $62,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Harmony Biosciences by 21.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock valued at $80,000 after purchasing an additional 360 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY opened at $34.20 on Friday. Harmony Biosciences Holdings, Inc. has a one year low of $28.14 and a one year high of $41.61. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of 16.21, a PEG ratio of 0.60 and a beta of 0.79. The company has a 50-day simple moving average of $34.15 and a 200-day simple moving average of $34.28. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.15. The business had revenue of $186.00 million for the quarter, compared to the consensus estimate of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.63 earnings per share. On average, analysts predict that Harmony Biosciences Holdings, Inc. will post 2.36 EPS for the current year.

Insider Buying and Selling

In other Harmony Biosciences news, insider Jeffrey Dierks sold 21,496 shares of Harmony Biosciences stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total transaction of $869,943.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 30.80% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on HRMY. Needham & Company LLC restated a “buy” rating and set a $52.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, October 29th. HC Wainwright started coverage on Harmony Biosciences in a report on Tuesday, December 17th. They set a “buy” rating and a $75.00 target price for the company. Mizuho upped their price objective on Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, October 10th. UBS Group started coverage on shares of Harmony Biosciences in a report on Tuesday, September 10th. They issued a “buy” rating and a $56.00 target price on the stock. Finally, Raymond James reaffirmed an “outperform” rating and set a $40.00 price target on shares of Harmony Biosciences in a report on Thursday, October 10th. Two equities research analysts have rated the stock with a sell rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.80.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.